115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39030)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39030)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world safety and efficacy of talquetamab for patients with heavily pretreated relapsed-refractory multiple myeloma
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Friend, R.; Snyder, J.; Davis, J.; Patrus, G.; Dileo, R.; Ahmed, N.; Mewawalla, P.; poonsombudlert, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Prompt and profound responses with talquetamab in patients with heavily pretreated relapsed-refractory multiple myeloma - Another bridging therapy
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Davis, J.; Snyder, J.; Friend, R.; Patrus, G.; DiLeo, R.; Mushtaq, M. U.; Green, K.; Mewawalla, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of BMS-986393 in patients with quadruple-class exposed relapsed or refractory multiple myeloma
    Meeting Abstract

    Patel, K.; Nadeem, O.; Munshi, N.; Iida, S.; Mailankody, S.; Neri, P.; Gregory, T.; Piasecki, J.; Ziyad, S.; Hu, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real world experience of talquetamab in relapsed refractory myeloma, first report from the IMWG Consortium
    Meeting Abstract

    Janakiram, M.; Tan, C.; Popat, R.; Kastritis, E.; Martínez-Lopez, J.; Shekarkhand, T.; Bansal, R.; De Menezes Silva Corraes, A.; de la puerta, M. C.; Sáez Marín, A. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Bispecific antibodies improve outcomes in patients with relapsed or refractory multiple myeloma after CAR-T cell therapy
    Meeting Abstract

    Merz, M.; Dima, D.; Hashmi, H.; Mueller, F.; Ahmed, N.; Rathje, K.; Davis, J.; Holderried, T.; Vucinik, V.; Kharbouti, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of ABBV-383, a BCMA bispecific antibody, in black patients with relapsed/refractory multiple myeloma: A subgroup analysis of a phase 1 trial
    Meeting Abstract

    D'Souza, A.; Rodriguez-Valdes, C.; Kumar, S.; Chung, A.; Tuchman, S.; Safah, H.; Weisel, K.; Teipel, R.; Korde, N.; Vij, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save